Multicenter prospective cohort study to identify high-risk group for primary gastric cancer using DNA methylation levels in normal-appearing gastric tissues in healthy people after Helicobacter pylori eradication - Risk prediction of gastric cancer after H. pylori eradication

Hoshi University0 sites1,880 target enrollmentMarch 24, 2015

Overview

No summary available.

Registry

who.int

Start Date

March 24, 2015

End Date

March 31, 2026

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

•1\) Synchronous or metachronous (within 5 years) malignancies, except for carcinoma in situ or mucosal tumors curatively treated with local therapy. 2\) Past history of gastrectomy, endoscopic treatment of a gastric tumor, and reconstructive surgery with a stomach tube for an esophageal cancer. 3\) Past history of receiving chemotherapy (including endocrinotherapy) or radiation therapy against any other malignancies. 4\) Suspicious gastric tumor by endoscopy or gastric biopsy at the time of eradication. 5\) Psychosis. 6\) Systemic steroid medication. 7\) Individuals with two or more kinds of antiplatelet medications, with anticoagulant medication, or with coagulopathy. 8\) Active gastrointestinal bleeding. 9\) Individuals considered unsuitable for biopsy by an endoscopist. 10\) Individuals with hereditary gastrointestinal tumors, including familial adenomatous polyposis (FAP), Lynch syndrome or Hereditary non\-polyposis colorectal cancer (HNPCC), Peutz\-Jeghers syndrome, Cowden syndrome, and Hereditary diffuse gastric cancer.